1
Clinical Trials associated with CIN-103A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are:
To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo.
To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo
Participants will attend the following visits:
Screening Period (1 Visit)
Baseline Period (1 Visit)
Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued participation.
12-Week Treatment Period (5 Visits)
Study drug taken twice daily by mouth.
Will complete daily diaries and other PROs as described in the protocol.
Follow- Up Period (1 Visit)
Researchers will compare CIN-103 Dose 1, CIN-103 Dose 2, and placebo, to evaluate the clinical response to multiple dose strengths of CIN-103 relative to placebo on abdominal pain and stool consistency along with safety and tolerability.
100 Clinical Results associated with CIN-103
100 Translational Medicine associated with CIN-103
100 Patents (Medical) associated with CIN-103
100 Deals associated with CIN-103